Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2756-2767

  Bucci, Barbara ^a   D'Agnano, Igea ^c,d   Amendola, Donatella ^a   Citti, Arianna ^a   Raza, Giorgio H ^a   Miceli, Roberto ^a   De Paula, Ugo ^a   Marchese, Rodolfo ^a   Albini, Sonia ^e   Felsani, Armando ^e   Brunetti, Ercole ^a   Vecchione, Aldo ^b  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Ist Neurbio e Medicina Molecolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; MYC PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53;

APOPTOSIS; ARTICLE; BASE MISPAIRING; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; ENZYME INHIBITION; GAMMA RADIATION; HUMAN; HUMAN CELL; MELANOMA CELL; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; RADIOSENSITIZATION; RADIOTHERAPY;

APOPTOSIS; BASE PAIR MISMATCH; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARRIER PROTEINS; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOWN-REGULATION; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MITOCHONDRIA; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA, ANTISENSE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20244377520     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1582     Document Type: Article

References (57)

1. Natham PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 2002;3:89-96.
2. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
3. Halmbach H, Rossman E, Korn M, Sehadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
4. Joiner MC, Van Der Kogel AJ. The linear quadratic approach to fractionation and calculation of isoeffect relationships. In: Staal GG, editor. Basic clinical radiobiology. London: Arnold; 1997. p.107-21.
5. Ballo MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am 2003;83:323-42.
6. Helmbach H, Kern MA, Rossmann E, et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002;118: 923-32.
7. Chana JS, Grover R, Tulley P, et al. The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma. Br J Plast Surg 2002;55:623-7.
8. Schlagbauer-Wadl H, Griffioen M, Van Elsas A. C-myc gene expression positively correlates with metastatic potential of human melanoma in SCID mice. Melanoma Res 1997;7:15-6.
9. Grover R, Ross DA, Richman PI, Robinson B, Wilson GD. C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity. Eur J Surg Oncol 1996;22:342-6.
10. Grover R, Ross DA, Wilson GD, Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 1997;50:478-82.
11. Grover R, Grobbelaar AO, Hudson DA, Forder M, Wilson GD, Sanders R. The clinical significance of oncogene expression in subungual melanoma. Br J Plast Surg 1997;50:15-9.
12. Grover R, Chana J, Grobbelaar AO, et al. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Br J Plast Surg 1999;52:122-6.
13. Chana JS, Grover R, Wilson GD, et al. The clinical significance of c-myc oncogene expression in melanomas of the scalp. Br J Plast Surg 1998;51:191-4.
14. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997;89:124-33.
15. Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of c-myc expression by anti-sense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995;55:1379-84.
16. Citro G, D'Agnano I, Leonetti C, et al. C-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998;58:283-9.
17. kip1 levels. Oncogene 2001;20:2814-25.
18. Mac Partlin M, Homer E, Robinson H, et al. Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene 2003;22:819-25.
19. Kuismanen SA, Holmberg MT, Salovaara R, De La Chapelle A, Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000;156:1773-9.
20. Bae I, Smith ML, Sheikh MS, et al. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines. Cancer Res 1996;56:840-7.
21. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987;38:137-47.
22. D'Agnano I, Antonelli A, Bucci B, et al. Effects of poly(ADP-ribose) polymerase inhibition on cell death and chromosome damage induced by VP16 and bleomycin. Environ Mol Mutagen 1998;32:56-63.
23. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-52.
24. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
25. Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates radiation-induced apoptosis. Blood 2000;95:2645-50.
26. Zink D, Mayr C, Janz C, Wiesmuller L. Association of p53 and MSH2 with recombinative repair complexes during S phase. Oncogene 2002;21:4788-800.
27. 1-phase checkpoint by low oxygen conditions is independent of p53 status. Moll Cell Biol 1994;14:6264-77.
28. Ohtsubo T, Wang X, Takahashi A, et al. P53-dependent induction of WAF1 by low pH culture condition in human glioblastoma cells. Cancer Res 1997;57:3910-13.
29. Lee HS, Park HJ, Griffin RJ, Lyons JC, Auger EA, Song CW. Radiation-induced apoptosis in different pH environments in vitro. Int J Radiat Oncol Biol Phys 1997;38:1079-87.
30. Juin P, Hueber AO, Littlewood T, Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev 1999;13:1367-81.
31. Chang DW, Claassen GF, Hann SR, Colo MD. The c-Myc transactivation domain is a direct modulator of apoptosis versus proliferative signals. Mol Cell Biol 2000;20:4309-19.
32. Villa R, Zaffaroni N, Bearzatto A, Costa A, Sichirollo A, Silvestrini R. Effect of ionizing radiation on cell-cycle progression and cyclin B1 expression in human melanoma cells. Int J Cancer 1996;66:104-9.
33. Louagie H, Cornelissen M, Philippe J, Vral A, Thierens H, De Ridder L. Flow cytometric scoring of apoptosis compared to electron microscopy in γ irradiated lymphocytes. Cell Biol Int 1998;22:277-83.
34. 2 arrest and radioresistance in two human cancer cells. Int J Radiat Oncol Biol Phys 1999;44:905-9.
35. 2 delay in HeLa cells. Cancer Res 1997;57:753-8.
36. Calaf GM, Hei TK. Ionizing radiation induces alterations in cellular proliferation and c-myc, c-jun and c-fos protein expression in breast epithelial cells. Int J Oncol 2004;25:1859-66.
37. 2 phase of the cell cycle. Mol Cell Biol 2001;21:4929-37.
38. 1-S arrest following ionizing radiation. Mol Cell Biol 2002;22:1819-33.
39. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblast. Proc Natl Acad Sci U S A 1995;92:8493-7.
40. 1 arrest and long term induction of Cip1 in normal human fibroblast. Genes Dev 1994;8:2540-51.
41. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992;70:923-35.
42. Yin XY, Grove L, Datta NS, Long MW, Prochownik. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 1999;18:1177-84.
43. Leonetti C, D'Agnano I, Lozupone F, et al. Anti-tumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996;88:419-29.
44. Yanagisawa Y, Ito E, Iwahashi Y, Akiyama Y, Yuasa Y, Maruyama K. Isolation and characterization of the 5′ region of the human mismatch repair gene hPMS1. Biochem Biophys Res Commun 1998;243:738-43.
45. Nicolaides NC, Kinzler KW, Vogelstein B. Analysis of the 5′ region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene. Genomics 1995;29:329-34.
46. Iwahashi Y, Ito E, Yanagisawa Y, et al. Promoter analysis of the human mismatch repair gene hMSH2. Gene 1998;213:141-7.
47. Acharya S, Wilson T, Gradia S, et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A 1996;93:13629-34.
48. Drummond JT, Li GM, Longley MJ, Modrich P. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 1995;268:1909-12.
49. Guerrette S, Wilson T, Gradia S, Fishel R. Interactions of human hMSH2 with hMSH3 and HMSH2 with hMSH6: examination of mutations found in hereditary nonpolyposis colorectal cancer. Mol Cell Biol 1998;18:6616-23.
50. 2 cell cycle checkpoint. Cancer Res 1995;55:3721-5.
51. cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13- acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ 1998;9:23-9.
52. Furukawa Y, Iwase S, Terui Y, et al. Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. J Biol Chem 1996;271:469-77.
53. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay, a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
54. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
55. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science 1991;253:49-53.
56. Lieberman DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
57. Zhu YM, Das-Gupta EP, Russel NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999;94:733-40.